Advice
Indication withdrawn
On 31 December, 2023, ocriplasmin (Jetrea) was voluntarily withdrawn and will no longer be available on the market after this date. Please see link
Medicine details
- Medicine name:
- ocriplasmin (Jetrea)
- SMC ID:
- 892/13
- Indication:
In adults for the treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns.
- Pharmaceutical company
- Thrombogenics NV
- BNF chapter
- Eye
- Submission type
- Resubmission
- Status
- Withdrawn
- Date advice published
- 11 August 2014
Additional notes
On 31 December, 2023, ocriplasmin (Jetrea) was voluntarily withdrawn and will no longer be available on the market after this date. Please see link